Sort   by:  
 Page size 
UnknownResults of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.
Not available
S-EPMC10289957 | biostudies-literature
UnknownA phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors.
Not available
S-EPMC6647865 | biostudies-literature
UnknownChanges of lung tumour volume on CT - prediction of the reliability of assessments.
Not available
S-EPMC4628325 | biostudies-literature
UnknownA phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors.
Not available
S-EPMC3909249 | biostudies-literature
UnknownA First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers.
Not available
S-EPMC6067949 | biostudies-literature
UnknownTIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial.
Not available
S-EPMC11815413 | biostudies-literature
UnknownThe future of cytotoxic therapy: selective cytotoxicity based on biology is the key.
Not available
S-EPMC165009 | biostudies-literature
UnknownA single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer.
Not available
S-EPMC3456920 | biostudies-literature
UnknownA First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors.
Not available
S-EPMC12580772 | biostudies-literature
UnknownA phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors.
Not available
S-EPMC5893148 | biostudies-literature
Sort   by:  
 Page size